Bafiertam vs Diroximel fumarate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline
Bafiertam
Marketed by Cycle Pharmaceuticals Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Diroximel fumarate · Vumerity
Marketed by Biogen and partners
NCT05083923 · Phase 3 · completed
The study was a single-group, open-label trial with 136 participants enrolled and no placebo or active comparator. Its primary outcomes were safety measures rather than a comparative clinical efficacy endpoint, so there was no formal primary treatment comparison to meet or miss; the reported safety findings are descriptive only.
Next expected readout: July 2034 · NCT07483632 (registry estimate)
Reported efficacy
Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B (End of treatment (up to Week 6) for both Parts A and B): Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. (met)
Result source: NCT03093324
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bafiertam | Diroximel fumarate |
|---|---|---|
| Annualised relapse rate | —Not reported | —Trial running · NCT07483632 |
| Free of 3-month confirmed disability progression (%) | —Not reported | —Trial running · NCT07483632 |
| New or enlarging T2 lesions | —Not reported | —Trial running · NCT07483632 |
Annualised relapse rate
- Bafiertam
- —Not reported
- Diroximel fumarate
- —Trial running · NCT07483632
Free of 3-month confirmed disability progression (%)
- Bafiertam
- —Not reported
- Diroximel fumarate
- —Trial running · NCT07483632
New or enlarging T2 lesions
- Bafiertam
- —Not reported
- Diroximel fumarate
- —Trial running · NCT07483632
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bafiertam: 2 of 4 rows · Diroximel fumarate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bafiertam | Diroximel fumarate |
|---|---|---|
| Dropout rate | —a NCT04570670 · Phase 1 | 9.6%Cohort 1: Japanese Participantsb NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more results20%Cohort 2: Chinese Participants NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 21.1%De Novo NCT02634307 · Phase 3 · monotherapy 29.7%Rollover: ALKS 8700 NCT02634307 · Phase 3 · monotherapy 27.1%Rollover: DMF NCT02634307 · Phase 3 · monotherapy 3.5% NCT03093324 · Phase 3 · monotherapy |
| Discontinued due to AEs | —a NCT04570670 · Phase 1 | 3.8%Cohort 1: Japanese Participantsb NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more results0%Cohort 2: Chinese Participants NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 8.4%De Novo NCT02634307 · Phase 3 · monotherapy 10%Rollover: ALKS 8700 NCT02634307 · Phase 3 · monotherapy 6.2%Rollover: DMF NCT02634307 · Phase 3 · monotherapy 1.6% NCT03093324 · Phase 3 · monotherapy |
| Serious AEs | 0%a NCT04570670 · Phase 1 | 11.5%Cohort 1: Japanese Participantsb NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more results12%Cohort 2: Chinese Participants NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 11.6%De Novo NCT02634307 · Phase 3 · monotherapy 12.1%Rollover: ALKS 8700 NCT02634307 · Phase 3 · monotherapy 11.1%Rollover: DMF NCT02634307 · Phase 3 · monotherapy 1.6% NCT03093324 · Phase 3 · monotherapy |
| Most frequent reported AEs | b diarrhoea 36.5% flushing 32.7% nasopharyngitis 21.2% NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 5 more resultsupper respiratory tract infection 36% flushing 18% lymphocyte count decreased 16% NCT05083923 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 flushing 38.1% multiple sclerosis relapse 15.7% nasopharyngitis 14.5% NCT02634307 · Phase 3 · monotherapy multiple sclerosis relapse 19.7% upper respiratory tract infection 17.6% lymphopenia 14.6% NCT02634307 · Phase 3 · monotherapy multiple sclerosis relapse 19.6% lymphopenia 16.9% upper respiratory tract infection 15.6% NCT02634307 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Diroximel fumarate
show 2 more results
show 2 more results
show 23 more results
show 23 more results
show 11 more results
show 11 more results
show 2 more results
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafiertam's landscape · Diroximel fumarate's landscape